Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A

5.86
CNY
-0.22
(-3.62%)
0.03EPS
531.44P/E
4.37BMarket Cap
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A
SSE:600613
(Shanghai Stock Exchange)

Recent

price

5.86

P/E

ratio

531.44

div

yld

1.26%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.62
0.84
1.34
2.01
2.87
3.23
2.98
3.21
3.49
3.67
3.41
4.3
4.43
4.52
3.73
3.57
3.21
Revenue per Share
0.03
0.1
0.2
0.24
0.4
0.44
0.34
0.24
0.2
0.16
-0.64
0.13
0.09
0.11
0.13
0.07
0.02
Basic EPS, GAAP
0.19
-0.03
0.12
0.04
-0.15
-0.07
-0.08
-0.08
0.07
0.1
0.01
0.18
0.54
0.37
0.31
0.17
- -
Free Cash Flow per Basic Share
- -
- -
0.06
0.02
- -
0.06
0.07
0.05
0.04
0.01
0.01
0.01
0.13
0.13
0.12
0.16
0.07
Dividend per Share
0.98
1.08
2.61
3.34
3.68
4.18
4.42
4.61
4.76
4.9
4.26
4.39
4.36
4.37
4.42
4.34
4.3
Book Value per Share
0.98
1.08
2.55
2.37
2.81
3.2
3.44
3.52
3.66
3.82
3.5
3.63
3.61
3.74
3.79
3.71
3.67
Tangible Book Value per Share
170
176
367
462
450
493
535
540
530
525
533
536
539
518
549
546
562
Basic Weighted Avg Shares
106
148
493
929
1,294
1,593
1,598
1,736
1,853
1,928
1,819
2,303
2,389
2,341
2,049
1,952
1,804
Sales/Revenue/Turnover
-0.69
12.27
21.1
14.09
16.91
16.7
13.01
10.47
8.11
10.33
0.62
3.64
4.17
4.98
6.56
5.67
5.34
Operating Margin (%)
10
9
22
27
32
39
45
46
48
55
53
66
96
93
91
87
- -
Depreciation Expense
6
18
73
112
180
217
182
130
106
84
-341
70
49
57
71
38
9
Net Income, GAAP
27.79
15.02
16.07
17.55
15.53
15.66
16.97
18.08
21.23
25.58
- -
31.76
23.62
30.15
24.55
43.79
67.99
Effective Tax Rate (%)
5.36
11.84
14.89
12
13.93
13.61
11.39
7.47
5.73
4.36
-18.76
3.02
2.03
2.43
3.48
1.96
0.48
Profit Margin (%)
88
114
341
933
1,135
1,235
1,337
1,281
1,251
1,296
961
966
996
1,086
1,065
1,033
981
Working Capital
- -
- -
30
- -
- -
- -
- -
- -
9
239
301
258
220
187
140
101
5
LT Debt
192
211
484
1,812
1,998
2,286
2,435
2,531
2,599
2,662
2,328
2,393
2,372
2,391
2,427
2,398
2,377
Total Equity
3.23
9.64
17.45
8.49
9.29
9.81
6.62
4.39
3.89
2.89
- -
2.75
2
2.31
2.76
1.68
0.66
Return on Invested Capital (%)
2.78
7.87
17.27
9.92
9.45
10.08
7.93
5.82
4.61
3.3
- -
2.85
2.31
2.49
3.27
1.61
0.17
Return on Capital (%)
3.32
9.61
22.45
9.92
9.61
10.33
7.93
5.38
4.24
3.26
-13.94
3.01
2.08
2.45
3.04
1.63
0.38
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
79
48
57
LT Borrowings
- -
- -
- -
LT Finance Leases
12
7
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
534
534
534
Market Capitalization
3,231
2,371
4,374

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,579
1,459
1,496
Cash, Cash Equivalents & STI
715
708
756
Accounts Receivable, Net
322
298
283
Inventories
218
207
211
Total Current Liabilities
606
496
515
Payables & Accruals
- -
- -
- -
ST Debt
79
48
57
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.6%
0.6%
-1.21%
Free Cash Flow
329.2%
705.54%
-46.76%
Net Income, GAAP
-74.46%
-30.89%
-46.43%
Sales/Revenue/Turnover
2.52%
2.23%
-4.71%
Total Cash Common Dividend
156.09%
327.21%
37.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
575
536
453
486
2,049
2025
480
481
- -
555
1,952
2026
423
425
401
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.04
0.02
0.13
2025
0.03
0.03
- -
-0.02
0.07
2026
0.02
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.1
0.01
0.01
0.12
2025
- -
0.16
- -
- -
0.16
2026
- -
0.07
- -
- -
- -
Business
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. engages primarily in the investment and management of pharmaceutical projects, focusing on the development and operation of pharmaceutical production, research, and distribution. The company specializes in pharmaceutical investment management services including financing, project incubation, and equity investment in pharmaceutical and healthcare sectors. Its core activities encompass the promotion and support of pharmaceutical product innovations, clinical research, and the commercialization of pharmaceutical technologies. The company operates mainly within China, leveraging its strategic positioning to invest in a range of pharmaceutical sub-sectors such as biopharmaceuticals, chemical pharmaceuticals, and healthcare services. Founded in 2001, the company is headquartered in Shanghai and positions itself as a critical intermediary in bridging capital with pharmaceutical innovation and production entities. It functions through fostering partnerships and strategic alliances with pharmaceutical manufacturers, research institutions, and healthcare providers. In the last one to two years, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. has pursued strategic expansions and partnerships aimed at broadening its investment portfolio and enhancing its influence in the healthcare investment space. This includes new funding rounds to support innovation-driven pharmaceutical projects and acquisitions to consolidate its market position. The company has also launched new service offerings related to clinical trial investment support and pharmaceutical product lifecycle management. These efforts signify a strategic shift toward deeper integration in the pharmaceutical value chain, enhancing its capabilities from pure investment to active project management and development. Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. caters primarily to pharmaceutical companies, research institutions, and healthcare enterprises seeking financial and operational support for their development and commercialization activities. It operates in a highly regulated environment, aligning with China’s healthcare policies and innovation incentives. The company’s role is pivotal in accelerating pharmaceutical innovation and bringing new therapies to market. In summary, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. is a Shanghai-based investment and management company founded in 2001, focusing on pharmaceutical investment management, project financing, incubation, and equity investments in pharmaceutical research, development, and production. Recent corporate developments include strategic expansions through partnerships, funding rounds, acquisitions, and new service product launches to extend operational capabilities in clinical trial investment and pharmaceutical lifecycle management. These changes reinforce its position as a comprehensive investment and management entity within China’s pharmaceutical industry.